company background image
PRQR

ProQR TherapeuticsNasdaqGM:PRQR Stock Report

Last Price

US$6.25

Market Cap

US$444.7m

7D

-10.2%

1Y

47.1%

Updated

19 Jan, 2022

Data

Company Financials +
PRQR fundamental analysis
Snowflake Score
Valuation2/6
Future Growth2/6
Past Performance0/6
Financial Health4/6
Dividends0/6

PRQR Stock Overview

ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders.

Price History & Performance

Summary of all time highs, changes and price drops for ProQR Therapeutics
Historical stock prices
Current Share PriceUS$6.25
52 Week HighUS$9.46
52 Week LowUS$4.05
Beta0.39
1 Month Change-18.30%
3 Month Change-18.41%
1 Year Change47.06%
3 Year Change-58.80%
5 Year Change48.81%
Change since IPO-57.57%

Recent News & Updates

Nov 10
Here's Why ProQR Therapeutics (NASDAQ:PRQR) Can Manage Its Debt Despite Losing Money

Here's Why ProQR Therapeutics (NASDAQ:PRQR) Can Manage Its Debt Despite Losing Money

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...

Oct 01

Investment Case On ProQR Therapeutics Gets More Enticing

Today, we revisit ProQR Therapeutics, an intriguing developmental concern for the first time since early this year. The company recently inked a significant collaboration deal with drug giant Eli Lilly which makes its investment case more enticing. We update the investment thesis on ProQR Therapeutics to account for recent events in the paragraphs below.

Shareholder Returns

PRQRUS BiotechsUS Market
7D-10.2%-6.2%-4.6%
1Y47.1%-19.8%7.7%

Return vs Industry: PRQR exceeded the US Biotechs industry which returned -18.4% over the past year.

Return vs Market: PRQR exceeded the US Market which returned 10.2% over the past year.

Price Volatility

Is PRQR's price volatile compared to industry and market?
PRQR volatility
PRQR Average Weekly Movement7.3%
Biotechs Industry Average Movement10.2%
Market Average Movement6.6%
10% most volatile stocks in US Market15.7%
10% least volatile stocks in US Market2.4%

Stable Share Price: PRQR is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 7% a week.

Volatility Over Time: PRQR's weekly volatility has decreased from 13% to 7% over the past year.

About the Company

FoundedEmployeesCEOWebsite
2012150Daniel de Boerhttps://www.proqr.com

ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. It is primarily developing sepofarsen that is in phase II/III illuminate trial for treating leber’s congenital amaurosis 10 disease; QR-421a, which is in phase I/II stellar trial for usher syndrome type 2 and non-syndromic retinitis pigmentosa; QR-1123 that is in phase I/II aurora trial for the treatment of autosomal dominant retinitis pigmentosa; and QR-504a, which is in first clinical trial for the treatment of fuchs endothelial corneal dystrophy. It has a license agreement with Radboud University Medical Center, Inserm Transfert SA, Ionis Pharmaceuticals, Inc., and Leiden University Medical Center, as well as ProQR Therapeutics VIII B.V. for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system.

ProQR Therapeutics Fundamentals Summary

How do ProQR Therapeutics's earnings and revenue compare to its market cap?
PRQR fundamental statistics
Market Cap€391.84m
Earnings (TTM)-€56.62m
Revenue (TTM)€2.19m

178.6x

P/S Ratio

-6.9x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
PRQR income statement (TTM)
Revenue€2.19m
Cost of Revenue€0
Gross Profit€2.19m
Expenses€58.81m
Earnings-€56.62m

Last Reported Earnings

Sep 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-0.80
Gross Margin100.00%
Net Profit Margin-2,580.54%
Debt/Equity Ratio15.1%

How did PRQR perform over the long term?

See historical performance and comparison

Valuation

Is ProQR Therapeutics undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: PRQR ($6.25) is trading below our estimate of fair value ($92.52)

Significantly Below Fair Value: PRQR is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: PRQR is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.

PE vs Market: PRQR is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate PRQR's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: PRQR is overvalued based on its PB Ratio (3x) compared to the US Biotechs industry average (2.1x).


Future Growth

How is ProQR Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?

35.1%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: PRQR is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: PRQR is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: PRQR is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: PRQR's revenue (59.5% per year) is forecast to grow faster than the US market (9.2% per year).

High Growth Revenue: PRQR's revenue (59.5% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: PRQR is forecast to be unprofitable in 3 years.


Past Performance

How has ProQR Therapeutics performed over the past 5 years?

-7.6%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: PRQR is currently unprofitable.

Growing Profit Margin: PRQR is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: PRQR is unprofitable, and losses have increased over the past 5 years at a rate of 7.6% per year.

Accelerating Growth: Unable to compare PRQR's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: PRQR is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (11%).


Return on Equity

High ROE: PRQR has a negative Return on Equity (-44.26%), as it is currently unprofitable.


Financial Health

How is ProQR Therapeutics's financial position?


Financial Position Analysis

Short Term Liabilities: PRQR's short term assets (€177.1M) exceed its short term liabilities (€34.7M).

Long Term Liabilities: PRQR's short term assets (€177.1M) exceed its long term liabilities (€32.6M).


Debt to Equity History and Analysis

Debt Level: PRQR has more cash than its total debt.

Reducing Debt: PRQR's debt to equity ratio has increased from 7.9% to 15.1% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: PRQR has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if PRQR has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Dividend

What is ProQR Therapeutics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate PRQR's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate PRQR's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if PRQR's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if PRQR's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of PRQR's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

3.1yrs

Average management tenure


CEO

Daniel de Boer (38 yo)

9.92yrs

Tenure

€2,624,000

Compensation

Mr. Daniel Anton de Boer has been the Chief Executive Officer and Member of Management Board at ProQR Therapeutics N.V. since February 21, 2012. He founded ProQR Therapeutics N.V. in February 2012. Mr. de...


CEO Compensation Analysis

Compensation vs Market: Daniel's total compensation ($USD2.98M) is above average for companies of similar size in the US market ($USD1.68M).

Compensation vs Earnings: Daniel's compensation has increased whilst the company is unprofitable.


Leadership Team

Experienced Management: PRQR's management team is considered experienced (3.1 years average tenure).


Board Members

Experienced Board: PRQR's board of directors are considered experienced (4.4 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 41.9%.


Top Shareholders

Company Information

ProQR Therapeutics N.V.'s employee growth, exchange listings and data sources


Key Information

  • Name: ProQR Therapeutics N.V.
  • Ticker: PRQR
  • Exchange: NasdaqGM
  • Founded: 2012
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: US$444.716m
  • Shares outstanding: 71.15m
  • Website: https://www.proqr.com

Number of Employees


Location

  • ProQR Therapeutics N.V.
  • Zernikedreef 9
  • Leiden
  • Zuid-Holland
  • 2333 Ck
  • Netherlands

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/01/19 23:48
End of Day Share Price2022/01/19 00:00
Earnings2021/09/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.